(Q42435697)

31 October 2017

title

N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells (English)

1 reference

31 October 2017

4

Jacob George

1 reference

31 October 2017

Adi Mor

1

1 reference

31 October 2017

Gad Keren

series ordinal

2

1 reference

31 October 2017

Yoel Kloog

series ordinal

3

1 reference

31 October 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

European Journal of Immunology

31 October 2017

published in

1 reference

31 October 2017

volume

38

1 reference

31 October 2017

issue

6

1 reference

31 October 2017

page(s)

1493-1502

1 reference

Multiple immuno-regulatory defects in type-1 diabetes

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

FOXP3 controls regulatory T cell function through cooperation with NFAT

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

FOXP3 modifies the phenotypic and functional properties of regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Foxp3 occupancy and regulation of key target genes during T-cell stimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Ras regulation and function in lymphocytes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Hyperactive Ras in developmental disorders and cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Signaling through RAS-RAF-MEK-ERK: from basics to bedside.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

NRAS mutation causes a human autoimmune lymphoproliferative syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Multiple p21ras effector pathways regulate nuclear factor of activated T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

RAS inhibitors: potential for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838292

7 January 2021

Identifiers

DOI

10.1002/EJI.200838292

1 reference

31 October 2017

1 reference